Shandong Xinbo Pharmaceutical Research Co., Ltd. has been selected as one of the "Top 10 Most Promising CGT CROs of 2023"
2023/03/28
On March 10, 2023, the CGCS 2023 (4th) International Summit on Cell and Gene Therapy in China was held in Nanjing. The CGCS organizing committee, in collaboration with Frost&Sullivan, ASGCT, and other institutions, has released the 2023 CGCS list, and Shandong Xinbo Pharmaceutical Research Co., Ltd. has been selected as one of the "Top 10 Most Promising CGT CROs of 2023".
According to Frost Sullivan's analysis, the market size of CGT (Cell and Gene Therapy) in China is showing a rapid growth trend.
The company will continue to enhance its non clinical safety evaluation service capabilities.
- Pre：Shandong Xinbo has completed the non clinical study of natural human monoclonal antibody CBB1 injection against rabies virus, helping to obtain clinical trial approval
- Next：Shandong Xinbo completes non clinical research on NMM tumor therapeutic DNA vaccine naked plasmid injection, helping to obtain clinical trial approval
